# A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

> **NCT07294508** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 706 (estimated)

## Conditions studied

- HER2 + Breast Cancer

## Interventions

- **DRUG:** HLX87 + HLX22
- **DRUG:** HLX87 + Pertuzumab
- **DRUG:** T-Dxd + Pertuzumab
- **DRUG:** THP

## Key facts

- **NCT ID:** NCT07294508
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-27
- **Primary completion:** 2028-01-15
- **Final completion:** 2030-12-30
- **Target enrollment:** 706 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294508, "A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07294508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*